BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2022 12:39:21 AM | Browse: 483 | Download: 1397
 |
Received |
|
2021-08-26 04:49 |
|
Peer-Review Started |
|
2021-08-26 04:51 |
|
First Decision by Editorial Office Director |
|
2021-10-29 03:42 |
|
Return for Revision |
|
2021-10-29 03:42 |
|
Revised |
|
2021-11-12 08:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-09 06:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-10 10:32 |
|
Articles in Press |
|
2022-02-10 10:32 |
|
Edit the Manuscript by Language Editor |
|
2022-01-17 03:41 |
|
Typeset the Manuscript |
|
2022-02-27 12:17 |
|
Publish the Manuscript Online |
|
2022-03-11 00:39 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lian-Fang Liu, Jia-Ying Deng, Analyn Lizaso, Jing Lin and Si Sun |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2017YFC0907900 |
| National Key R&D Program of China |
2017YFC0907904 |
|
| Corresponding Author |
Si Sun, MD, Chief Doctor, Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, No. 270 Dong An Road, Shanghai 200032, China. sunsi123sun@hotmail.com |
| Key Words |
Poorly differentiated; Non-small cell carcinoma; Mesenchymal-epithelial transition factor fusion; Crizotinib; Case report |
| Core Tip |
The most common mesenchymal-epithelial transition factor (MET) gene aberrations are gene amplifications and exon 14 splice variants found in approximately 2% to 10% of lung cancer patients. Chromosomal rearrangements resulting in gene fusions involving MET are generally rare but could account for MET-driven oncogenesis. The rarity and diversity of MET fusions in non-small cell lung cancer (NSCLC) limit the volume of evidence documenting the clinical efficacy of crizotinib in treating MET-rearranged NSCLC patients. Herein, we report the clinical response to crizotinib of a patient with advanced poorly differentiated NSCLC harboring concurrent MET-involving rearrangements, including a novel MET-CDR2 gene fusion. |
| Publish Date |
2022-03-11 00:39 |
| Citation |
Liu LF, Deng JY, Lizaso A, Lin J, Sun S. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report. World J Clin Cases 2022; 10(8): 2529-2536 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i8/2529.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i8.2529 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
